| View |
BR-1250_PI_01.pdf
|
BR-1250
|
Follitropin Alfa
|
Follitrope
|
300 IU / 0.6 mL
|
Solution for Injection (SC/IM)
|
Prescription Drug (RX)
|
1 mL (Net content: 0.6 mL) Pre-filled borosilicate glass syringe with elastomer rubber stopper (Box of 1's)
|
-
|
LG Chem, Ltd.
|
Korea
|
N/A
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Initial (from Monitored Release)
|
15 March 2023
|
06 October 2027
|
| View |
|
BR-1251
|
Heparin Sodium
|
None
|
1000 IU/mL
|
Solution For Injection (IV/SC)
|
Prescription Drug (RX)
|
Type I clear glass vial x 5 mL (Box of 10's) Type I clear glass vial x 30 mL (Box of 20's)
|
-
|
AIN Medicare Sdn. Bhd.
|
Malaysia
|
N/A
|
Dega International Pharma Corp.
|
Dega International Pharma Corp.
|
Renewal
|
27 June 2022
|
06 August 2027
|
| View |
|
BR-1252
|
Nimotuzumab
|
TheraCIM
|
50 mg/10 mL
|
Solution For IV Infusion
|
Prescription Drug (RX)
|
EP Type I Glass Vial
|
-
|
Center of Molecular Immunology (CIM)
|
Cuba
|
(For) Innogene Kalbiotech Pte. Ltd.- Singapore
|
Globo Asiatico Ent. Inc.
|
Globo Asiatico Ent. Inc.
|
Automatic Renewal
|
14 October 2022
|
28 September 2027
|
| View |
|
BR-1254
|
Menotrophin
|
Humog 150
|
150 IU
|
Solution for Injection
|
Prescription Drug (RX)
|
Box of 1's
|
GONADOTROPHIN
|
Bharat Biotech International Ltd.
|
India
|
|
BSV Bioscience Philippines Inc.
|
Sandoval Distributors & Pharmacy
|
Automatic Renewal
|
27 December 2022
|
04 January 2028
|
| View |
|
BR-1255
|
Menotrophin
|
Humog 75
|
75 IU
|
Solution for Injection
|
Prescription Drug (RX)
|
Box of 1's
|
GONADOTROPHIN
|
Bharat Biotech International Ltd.
|
India
|
|
BSV Bioscience Philippines Inc.
|
Sandoval Distributors & Pharmacy
|
Automatic Renewal
|
16 December 2022
|
04 January 2028
|
| View |
|
BR-1259
|
Chorionic Gonadotrophin
|
Hucog-5,000 Hp
|
5,000 IU
|
Solution For Injection/ 5000 I.U.
|
Prescription Drug (RX)
|
Box of 1's
|
Gonadotropins
|
Bharat Serums and Vaccine Limited
|
India
|
|
BSV Bioscience Philippines Inc.
|
Sandoval Distributors & Pharmacy
|
Automatic Renewal
|
13 December 2022
|
26 January 2028
|
| View |
|
BR-1261
|
Urofollitropin
|
Foliculin -75 HP
|
75 IU
|
Lyophilized Powder for Solution for Injection (IM/SC)
|
Prescription Drug (RX)
|
Packaging: 2 mL USP Type I clear glass tubular vial with bromobutyl rubber bung and brown aluminum flip-off seal + 1 mL ampoule of diluent (0.9% Sodium Chloride Solution for Injection) (Box of 1's)
|
Gonadotropins
|
Bharat Serums and Vaccines Limited
|
India
|
N/A
|
BSV Bioscience Phils. Inc.
|
Sandoval Distributors, Inc.
|
Initial
|
18 February 2022
|
05 March 2026
|
| View |
|
BR-1263
|
Diphtheria, Tetanus, Pertussis, Hepatitis B Recombinant and Haemophilus influenza B Tyoe (Hib) Vaccine
|
Eupenta
|
|
Solution for IM Injection
|
Prescription Drug (RX)
|
0.5 mL colorless glass vial, with grey chlorobutyl rubber stopper and aluminum flip-off with propylene flip-off cap x 1's (box of 10's); single dose
|
Vaccine
|
LG Chem Limited
|
Korea
|
|
Glovax Biotech Corp
|
|
Renewal
|
03 January 2023
|
13 March 2028
|
| View |
|
BR-1264
|
Diphtheria, Tetanus, Pertussis, Hepatitis B Recombinant and Haemophilus influenza B Tyoe (Hib) Vaccine
|
Eupenta
|
|
Solution for IM Injection
|
Prescription Drug (RX)
|
5mL USP Type I Vial with grey chlorobutyl rubber stopper and aluminum flip-off seal cap x 1's (box of 10's); Multidose
|
Vaccine
|
LG Chem Limited
|
Korea
|
|
Glovax Biotech Corp
|
|
Renewal
|
04 January 2023
|
13 March 2028
|
| View |
BR-1265_PI_01.pdf
|
BR-1265
|
Adalimumab
|
Humira
|
40mg/ 0.4mL
|
Solution for Injection, Pre-Filled Pen (Mai)
|
Prescription Drug (Rx)
|
In a box of 2 blister trays each having a single-use modified auto-injector pen containing 1 mL type I pre-filled syringe x 0.4 mL with plunger stopper, a fixed 29G 1/2 needle witn needle shield (thermoplastic elastomer) and an alcohol swab
|
Antirheumatic
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
|
Abbott Laboratories
|
|
Monitored Release
|
24 September 2019
|
22 March 2025
|
| View |
BR-1266_PI_01.pdf
|
BR-1266
|
Evolocumab
|
Repatha
|
140 mg/mL
|
Solution for Injection in Pre-filled Autoinjector
|
Prescription Drug (Rx)
|
Prefilled autoinjector/pen (AI/Pen)
with a Type 1 glass prefilled
syringe (PFS)
|
Anti-PCSK9 Monoclonal Antibody
|
Amgen Manufacturing Ltd.
|
U.S.A.
|
|
|
ZUELLIG PHARMA CORPORATION
|
Monitored Release
|
23 April 2018
|
23 April 2025
|
| View |
BR-1267_PI_01.pdf
|
BR-1267
|
Evolocumab
|
Repatha
|
140 mg/mL
|
Pre-filled Syringe for Injection
|
Prescription Drug (Rx)
|
1 mL Type I glass syringe
|
Anti-PCSK9 Monoclonal Antibody
|
Amgen Manufacturing Ltd.
|
U.S.A.
|
|
|
ZUELLIG PHARMA CORPORATION
|
Monitored Release
|
23 April 2018
|
23 April 2025
|
| View |
|
BR-1268
|
Insulin aspart
|
Fiasp Flextouch
|
100 Units/mL
|
Solution for Injection (SC/IV)
|
Prescription (Rx) Drug
|
3 I 3 mL-net content Type I glass cartridge with halobutyl plunger, and halobutyl/polyisoprene stopper contained in
pre-filled
multidose disposable pen made of polypropylene, polyoxymethylene, polycarbonate and acrylonitrile butadiene styrene (Box of 5's)
|
-
|
Novo Nordisk A/S
|
Denmark
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Renewal
|
19 October 2023
|
09 May 2028
|
| View |
|
BR-1269
|
Insulin aspart
|
Fiasp
|
100 Units/mL
|
Solution for Injection (IV/SC)
|
Prescription (Rx) Drug
|
10 mL-net content Type I glass
halobutyl/polyisoprene rubber disc and protective plastic.
cap (Box of 1's)
|
Insulins and Analogues
|
Novo Nordisk A/S
|
Denmark
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Renewal
|
07 November 2023
|
09 May 2028
|
| View |
BR-1270_PI_01.pdf
|
BR-1270
|
Insulin Glargine/ Lixisenatide
|
Soliqua
|
3.64 mg (equivalent to 100 Units of Insulin glargine) / 50 mcg per mL
|
Solution for Injection (SC)
|
Prescription (Rx) Drug
|
3 mL-net content Type I glass cartridge with black bromobutyl rubber plunger stopper, aluminum flanged cap with punched laminated sealing disk assembled into a disposable pen-injector made of polypropylene (Box of 1's, 3's and 5's).
|
Long-acting Insulin and Analogue.
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
|
Sanofi-Aventis Philippines, Inc.
|
Sanofi-Aventis Philippines, Inc.
|
Initial (from Monitored Release)
|
06 March 2024
|
09 May 2028
|
| View |
BR-1271_PI_01.pdf
|
BR-1271
|
Insulin Glargine/ Lixisenatide
|
Soliqua
|
3.64 mg (equivalent to 100 Units of Insulin glargine) / 33 mcg per mL
|
Solution for Injection (SC)
|
Prescription (Rx) Drug
|
3 mL-net content Type I glass cartridge with black bromobutyl rubber plunger stopper, aluminum flanged cap with punched laminated sealing disk assembled into a disposable pen-injector made of polypropylene (Box of 1's, 3's and 5's).
|
Long-acting Insulin and Analogue
|
Sanofi-Aventis Deutschland GmbH
|
Germany
|
|
Sanofi-Aventis Philippines, Inc.
|
Sanofi-Aventis Philippines, Inc.
|
Initial (from Monitored Release)
|
06 March 2024
|
09 May 2028
|
| View |
|
BR-1275
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1275
|
31 December 2022
|
07 June 2028
|
| View |
|
BR-1276
|
Human Albumin
|
Alburx
|
250 g/L (25 % w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring AG
|
Switzerland
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Automatic Renewal
|
05 January 2023
|
07 June 2028
|
| View |
|
BR-1277
|
Human Albumin
|
Alburx
|
200 g/L (20% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1277
|
03 January 2023
|
07 June 2028
|
| View |
|
BR-1278
|
Human Albumin
|
Alburx
|
250 g/L (25% w/v)
|
Solution for Intravenous Infusion
|
Prescription Drug (Rx)
|
Type II Glass Vials
|
Plasma fractions for specific uses
|
CSL Behring LLC
|
U.S.A.
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
BR-1278
|
31 December 2022
|
07 June 2028
|